Payment overview · 2025
General Payments
$32,414.20
249 reported records · 32 companies
Healthcare provider profile · identity verified
Mark Jon Pamer, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · PORT SAINT LUCIE, FL · NPI 1184824542
Verified facts
What the public records show
CMS Open Payments records show Mark Jon Pamer, D.O. received $32,414.20 in general payments during 2025 across 249 reported records.
Viatris Specialty LLC accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Nuzyra, Ofev, Opsumit, Shingrix, Tezspire, Trelegy Ellipta.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Opsumit by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 22824 records involving 7320 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Tezspire by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 33983 records involving 10291 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Tezspire by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 789 claims for Trelegy Ellipta by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adempas as an associated drug or biological on 14 records involving 2 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Adempas by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
Paratek Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUZYRA as an associated drug or biological on 24089 records involving 10216 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nuzyra by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Gammagard Liquid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $10,873.90 | 33.5% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $7,845.23 | 24.2% | 24 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $7,556.60 | 23.3% | 31 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $2,062.54 | 6.4% | 19 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $778.11 | 2.4% | 17 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $521.40 | 1.6% | 26 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $368.21 | 1.1% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $304.28 | 0.9% | 21 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $227.10 | 0.7% | 13 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $196.69 | 0.6% | 9 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $189.33 | 0.6% | 13 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $166.96 | 0.5% | 7 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $162.37 | 0.5% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $142.03 | 0.4% | 6 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $128.61 | 0.4% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $101.25 | 0.3% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $99.95 | 0.3% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $98.49 | 0.3% | 4 | 2025 |
| Grifols Shared Services North America, Inc. | Unresolved — no canonical attribution shown | $88.47 | 0.3% | 1 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $75.87 | 0.2% | 3 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $68.40 | 0.2% | 3 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $65.96 | 0.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $53.81 | 0.2% | 2 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $49.80 | 0.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.01 | 0.1% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.25 | 0.1% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $24.08 | 0.1% | 1 | 2025 |
| GC Biopharma USA, Inc. | Unresolved — no canonical attribution shown | $22.72 | 0.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.02 | 0.1% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $18.00 | 0.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.15 | 0.1% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $15.61 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18,515.76 | 7 |
| Food and Beverage | $6,805.05 | 233 |
| Consulting Fee | $5,100.00 | 1 |
| Travel and Lodging | $1,793.49 | 6 |
| Education | $199.90 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $10,873.90 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $7,587.99 | 13 | 2025 |
Source payment records
|
|||||
| TYVASO Normalized: tyvaso |
Drug | United Therapeutics Corporation | $7,176.44 | 25 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols Shared Services North America, Inc., Grifols USA, LLC | $2,099.95 | 17 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $600.83 | 12 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $521.40 | 26 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., SANOFI-AVENTIS U.S. LLC | $395.52 | 12 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $391.33 | 6 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $237.35 | 8 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $217.64 | 7 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $201.53 | 14 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological, Drug | Octapharma USA, Inc., PFIZER INC. | $191.04 | 11 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc., PFIZER INC. | $189.54 | 11 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $189.33 | 13 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $165.39 | 10 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $162.37 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $142.03 | 6 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $125.12 | 4 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $98.49 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $93.91 | 6 | 2025 |
Source payment records
|
|||||
| STEEN SOLUTION Normalized: steen solution |
Device | United Therapeutics Corporation | $91.12 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $85.19 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $78.14 | 2 | 2025 |
Source payment records
|
|||||
| XOLAIR Normalized: xolair |
Biological, Drug | Genentech USA, Inc., Novartis Pharmaceuticals Corporation | $77.89 | 3 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $76.09 | 3 | 2025 |
Source payment records
|
|||||
| Zemaira Normalized: zemaira |
Biological | Vifor Pharma, Inc. | $75.87 | 3 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $68.40 | 3 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $68.10 | 3 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $65.96 | 2 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Optinose US, Inc., Paratek Pharmaceuticals, Inc. | $64.79 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $61.71 | 3 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $59.66 | 3 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $51.06 | 3 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $45.23 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $32.25 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.80 | 2 | 2025 |
Source payment records
|
|||||
| CUVITRU Normalized: cuvitru |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $25.45 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| ALYGLO Normalized: alyglo |
Drug | GC Biopharma USA, Inc. | $22.72 | 1 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $8.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 37 | exact normalized | Medicare Part D |
| NUZYRA nuzyra |
2025 | Nuzyra | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OFEV ofev |
2025 | Ofev | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OPSUMIT opsumit |
2025 | Opsumit | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TEZSPIRE tezspire |
2025 | Tezspire | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 789 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 22824 supporting records · 7320 recipient NPIs · example record 1226871881 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 33983 supporting records · 10291 recipient NPIs · example record 1206131392 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
37 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
789 | 190 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | Adempas open payments reported associated product |
CMS Open Payments — General Payments 14 supporting records · 2 recipient NPIs · example record 1237996458 |
Adempas · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 13 |
| Paratek Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | NUZYRA open payments reported associated product |
CMS Open Payments — General Payments 24089 supporting records · 10216 recipient NPIs · example record 1181734338 |
Nuzyra · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 789 | 190 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 535 | 211 |
| Breo Ellipta | Fluticasone/Vilanterol | 312 | 74 |
| Prednisone | Prednisone | 284 | 174 |
| Ipratropium Bromide | Ipratropium Bromide | 279 | 103 |
| Fluticasone Propionate | Fluticasone Propionate | 206 | 102 |
| Montelukast Sodium | Montelukast Sodium | 187 | 78 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 187 | 51 |
| Azithromycin | Azithromycin | 183 | 100 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 177 | 46 |
| Losartan Potassium | Losartan Potassium | 135 | 50 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 129 | 39 |
| Rabeprazole Sodium | Rabeprazole Sodium | 112 | 48 |
| Ventolin Hfa | Albuterol Sulfate | 100 | 33 |
| Levofloxacin | Levofloxacin | 79 | 59 |
| Gabapentin | Gabapentin | 76 | 28 |
| Omeprazole | Omeprazole | 72 | 31 |
| Torsemide | Torsemide | 69 | 24 |
| Theophylline Er | Theophylline Anhydrous | 68 | 20 |
| Alprazolam | Alprazolam | 62 | 28 |
| Dexamethasone | Dexamethasone | 58 | 43 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 42 |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 45 |
| Ofev | Nintedanib Esylate | 52 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 52 | 29 |
| Famotidine | Famotidine | 49 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 49 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 20 |
| Temazepam | Temazepam | 45 | 12 |
| Opsumit | Macitentan | 43 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 40 | 15 |
| Doxepin Hcl | Doxepin Hcl | 40 | 16 |
| Ambrisentan | Ambrisentan | 38 | suppressed |
| Clonazepam | Clonazepam | 38 | 14 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 37 | 37 |
| Desipramine Hcl | Desipramine Hcl | 37 | 16 |
| Dupixent Syringe | Dupilumab | 37 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 14 |
| Pregabalin | Pregabalin | 37 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 36 | 13 |
| Furosemide | Furosemide | 35 | 17 |
| Tezspire | Tezepelumab-Ekko | 35 | suppressed |
| Eliquis | Apixaban | 34 | 15 |
| Roflumilast | Roflumilast | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | 12 |
| Lorazepam | Lorazepam | 32 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 24 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 23 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Epinephrine | Epinephrine | 20 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Metformin Hcl | Metformin Hcl | 18 | suppressed |
| Amikacin Sulfate | Amikacin Sulfate | 17 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Modafinil | Modafinil | 16 | suppressed |
| Nystatin | Nystatin | 16 | 11 |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 16 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Tigecycline | Tigecycline | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Nuzyra | Omadacycline Tosylate | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Rifampin | Rifampin | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Adempas | Riociguat | 11 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Pirfenidone | Pirfenidone | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $32,414.20 · 249 records | Viatris Specialty LLC | ABRYSVO, ACTHAR, AIRSUPRA, ALYGLO, AREXVY, Arikayce, BREZTRI, Brinsupri, CAPVAXIVE, COMIRNATY, CUTAQUIG, CUVITRU, DUPIXENT, FASENRA, GLASSIA, HYQVIA, Hillrom - Vest System Model 105 Home Care, Hizentra, INSPIRE, JASCAYD, NUCALA, NUZYRA, OCTAGAM IMMUNE GLOBULIN (HUMAN), OFEV, OPSUMIT, OPSYNVI, Ohtuvayre, PANZYGA, PREVNAR 20, Prolastin-C Liquid, SHINGRIX, SMARTVEST, STEEN SOLUTION, Sunosi, TAGRISSO, TEZSPIRE, TRELEGY ELLIPTA, TYVASO, UPTRAVI, WINREVAIR, XHANCE, XOLAIR, XYWAV, Xembify, YUPELRI, ZEPBOUND, Zemaira | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Actelion Pharmaceuticals US, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error